neutral
antibodi
associ
prevent
clearanc
influenza
viru
infect
microneutr
mn
hemagglutin
inhibit
hi
assay
current
use
evalu
neutral
antibodi
respons
human
avian
influenza
virus
includ
mn
assay
somewhat
labor
intens
hi
surrog
neutral
moreov
use
replic
compet
virus
assay
requir
biosafeti
level
contain
therefor
neutral
assay
requir
facil
would
advantag
toward
goal
gener
panel
pseudotyp
express
influenza
hemagglutinin
ha
neuraminidas
na
develop
pseudotypebas
neutral
pn
assay
demonstr
hana
pseudotyp
mimic
releas
entri
influenza
viru
pn
assay
exhibit
good
specif
reveal
quantit
differ
neutral
antibodi
titer
differ
clade
subclad
use
immun
ferret
sera
demonstr
excel
correl
pn
mn
hi
assay
thu
conclud
pn
assay
sensit
quantifi
method
measur
neutral
antibodi
divers
clade
subclad
influenza
viru
sinc
highli
pathogen
avian
influenza
hpai
virus
isol
infect
domest
poultri
numer
countri
asia
europ
africa
result
increas
number
avian
human
transmiss
occur
often
high
mortal
present
hpai
transmiss
limit
avian
human
howev
continu
adapt
viru
reassort
season
human
influenza
strain
may
result
new
strain
capabl
effici
humantohuman
transmiss
result
strain
could
caus
influenza
pandem
signific
level
morbid
mortal
neutral
antibodi
respons
critic
prevent
clearanc
influenza
viru
infect
measur
neutral
antibodi
respons
may
use
influenza
serodiagnosi
current
microneutr
mn
hemagglutin
inhibit
hi
assay
use
estim
neutral
antibodi
respons
hpai
virus
microneutr
mn
assay
confirm
western
blot
analysi
consid
gold
standard
detect
specif
neutral
antibodi
respons
human
howev
assay
somewhat
laborintens
requir
use
variou
strain
replic
compet
virus
biosafeti
level
contain
limit
common
use
test
mani
affect
countri
evalu
cytopath
effect
cpe
reach
endpoint
titer
mn
assay
requir
signific
train
perform
consist
accuraci
hi
assay
base
measur
abil
antibodi
inhibit
hemmaglutin
erythocyt
influenza
virus
serv
surrog
neutral
influenza
viru
unfortun
convent
hi
assay
use
chicken
erythrocyt
indic
cell
use
season
influenza
strain
found
poorli
suit
use
avian
infect
therefor
modifi
hi
assay
use
hors
erythrocyt
develop
addit
hi
assay
distinguish
infecti
noninfecti
viru
particl
therefor
develop
standard
quantifi
assay
measur
neutral
antibodi
respons
requir
contain
urgent
need
serodiagnosi
human
hpai
infect
well
vaccin
evalu
lentivir
pseudotyp
express
heterolog
glycoprotein
mani
virus
develop
includ
vesicular
stomat
viru
vsv
hepat
c
viru
hcv
sar
coronaviru
ebola
avian
influenza
viru
influenza
viru
murin
leukemia
viru
mlv
lassa
fever
viru
lentivir
pseudotyp
becom
use
tool
studi
viral
entri
releas
antivir
drug
screen
serodiagnosi
use
assess
respons
vaccin
recent
develop
lentivir
pseudotyp
express
report
pseudotyp
undergo
singleround
infect
produc
progeni
virus
indic
cell
line
thu
assay
base
pseudotyp
particl
requir
facil
product
test
pseudotyp
particl
also
engin
contain
report
gene
green
fluoresc
protein
gfp
luciferas
gene
therefor
infect
transduct
effici
pseudotyp
readili
assess
measur
fluoresc
indic
express
report
gene
studi
gener
panel
pseudotyp
particl
express
ha
na
well
influenza
virus
use
panel
develop
influenza
ha
na
pseudotypebas
neutral
pn
assay
demonstr
ha
na
pseudotyp
mimic
wild
type
influenza
viru
releas
entri
pn
assay
specif
clade
subclad
influenza
viru
addit
excel
correl
neutral
titer
measur
pn
mn
assay
final
use
sera
ferret
immun
vaccin
demonstr
pn
assay
provid
sensit
quantifi
method
measur
neutral
antibodi
divers
clade
subclad
influenza
viru
packag
cell
line
maintain
complet
dulbecco
modifi
eagl
medium
dmem
ie
high
glucos
dmem
supplement
fb
mm
lglutamin
mm
sodium
pyruv
penicillin
uml
streptomycin
gml
invitrogen
life
technolog
contain
mgml
cell
origin
report
deng
et
al
obtain
nih
aid
research
refer
reagent
program
maintain
complet
dmem
supplement
mgml
mgml
hygromycin
b
gml
puromycin
madindarbi
canin
kidney
mdck
cell
maintain
complet
dmem
medium
humidifi
incub
c
co
lentiviru
transfer
vector
phr
cmvluc
packag
vector
pcmvr
gener
gift
dr
l
naldini
univers
torino
medic
school
torino
itali
codon
optim
ha
human
isol
ahong
determin
use
gcg
packag
genet
comput
group
inc
madison
wi
gener
recurs
pcr
clone
ta
vector
system
previous
describ
insert
contain
correct
sequenc
reclon
mammalian
express
vector
cmvr
deriv
result
plasmid
construct
design
ahong
respect
isol
gene
encod
human
isol
viral
rna
isol
heatinactiv
viruscontain
supernat
complementari
dna
encod
gener
rtpcr
use
pair
haspecif
primer
describ
hoffmann
et
al
insert
ta
vector
sequenc
insert
contain
correct
ha
sequenc
reclon
express
vector
cmvr
describ
result
plasmid
construct
design
ha
multibas
cleavag
site
mutant
human
influenza
strain
gener
overlap
pcr
gene
encod
wild
type
ha
wsn
strain
templat
gift
obtain
dr
tetseuya
toyoda
institut
pasteur
shanghai
insert
ta
vector
sequenc
insert
contain
correct
ha
sequenc
reclon
express
vector
cmvr
facilit
na
detect
codon
optim
na
human
isol
flag
epitop
n
dykddddkc
insert
stalk
region
amino
acid
residu
describ
luo
et
al
gener
recurs
pcr
clone
ta
vector
sequenc
insert
contain
correct
flag
epitopetag
sequenc
reclon
mammalian
express
vector
cmvr
initi
studi
found
similar
transduct
effici
flagtag
pseudotyp
data
shown
thu
use
flagtag
subsequ
experi
sake
simplic
text
use
na
describ
flagtag
produc
ha
na
pseudotyp
first
test
requir
na
andor
pseudotyp
lentivir
vector
packag
cell
cotransfect
g
phr
cmvluc
g
pcmv
g
cmvrha
variou
indic
dose
cmvrna
found
cotransfect
cmvrna
significantli
enhanc
transduct
effici
optim
ratio
amount
cmvrha
cmvrna
plasmid
use
cotransfect
supplementari
figur
therefor
subsequ
ha
na
pseudotyp
product
packag
cell
cotransfect
g
phr
cmvluc
g
pcmv
g
cmvrha
g
cmvrna
use
calcium
phosphat
precipit
method
control
cell
also
cotransfect
g
phr
cmvluc
g
pcmv
g
dna
plasmid
encod
vsvg
envelop
overnight
incub
cell
wash
pb
cultur
ml
complet
dmem
supplement
sodium
butyr
sigma
st
loui
mo
h
cell
cultur
ml
complet
dmem
pseudotypecontain
supernat
harvest
h
store
c
freezer
aliquot
use
transduct
neutral
assay
see
test
effect
exogen
na
treatment
pseudotyp
releas
cell
cotransfect
phr
cmvluc
pcmv
cmvrha
ha
alon
describ
overnight
incub
cell
cultur
ml
complet
dmem
supplement
sodium
butyr
h
cell
cultur
ml
complet
dmem
presenc
uml
vibrio
cholera
na
sigma
describ
dong
et
al
pseudotypecontain
supernat
harvest
h
cellular
debri
pellet
centrifug
g
min
character
pseudotyp
collect
supernat
load
onto
sucros
cushion
ultracentrifug
rpm
h
c
beckman
swing
rotor
beckman
coulter
fullerton
ca
depend
volum
supernat
collect
pellet
dissolv
pb
fraction
sucros
densiti
gradient
rpm
h
c
beckman
swing
rotor
twelv
fraction
ml
collect
top
bottom
gradient
tca
precipit
separ
sdspage
follow
western
blot
analysi
see
singlecycl
assay
measur
transduct
effici
pseudotyp
mdck
cell
transduc
variou
amount
pseudotypecontain
supernat
presenc
gml
polybren
overnight
cell
wash
pb
cultur
complet
dmem
medium
day
cell
wash
pb
without
phenol
red
suspend
l
lysi
buffer
singl
round
freezethaw
luciferas
activ
l
cell
lysat
measur
brightglo
luciferas
assay
accord
manufactur
instruct
promega
madison
wi
determin
whether
ha
na
pseudotyp
enter
cell
receptormedi
endocytosi
lysosomotrop
agent
ammonium
chlorid
nh
cl
vacuolar
h
atpas
inhibitor
bafilomycin
sigma
use
treat
target
cell
transduct
work
solut
prepar
dimethyl
sulfoxid
dmso
store
c
stock
solut
nh
cl
prepar
distil
water
steril
filter
assess
effect
nh
cl
entri
ha
na
envelop
pseudotyp
mdck
cell
per
well
seed
onto
plate
pretreat
without
variou
indic
amount
nh
cl
h
transduct
transduct
l
ha
na
pseudotypeor
envelop
pseudotypecontain
supernat
ad
well
incub
c
overnight
presenc
drug
supernat
remov
replac
fresh
complet
medium
h
transduct
cell
harvest
luciferas
activ
transduc
cell
measur
describ
test
effect
na
inhibitor
pseudotyp
releas
packag
cell
cotransfect
phr
cmvluc
pcmv
cmvrha
cmvrna
phr
cmvluc
pcmv
envelop
describ
overnight
incub
cell
cultur
ml
complet
dmem
supplement
sodium
butyr
h
cell
cultur
overnight
ml
complet
dmem
presenc
variou
indic
dose
na
inhibitor
oseltamivir
phosphat
roch
diagnost
cultur
supernat
collect
use
transduc
target
cell
overnight
describ
supernat
remov
replac
fresh
complet
medium
h
transduct
cell
harvest
luciferas
activ
transduc
cell
measur
describ
character
ha
na
pseudotyp
ha
na
pseudotypecontain
supernat
harvest
concentr
fraction
sucros
densiti
gradient
describ
protein
concentr
supernat
fraction
sampl
resolv
sdspage
transfer
onto
pdvf
membran
blot
block
solut
trisbuff
salin
contain
nonfat
dri
milk
tween
subsequ
probe
monoclon
antibodi
clone
specif
gag
mous
antiflag
tag
monoclon
antibodi
sigma
mous
immun
sera
specif
see
antigen
visual
apconjug
antimous
igg
antibodi
promega
accord
manufactur
instruct
character
ha
na
pseudotyp
electron
microscopi
packag
cell
cotransfect
phr
cmvluc
pcmv
cmvrha
cmvrna
describ
transfect
cell
wash
three
time
pb
fix
glutaraldehyd
pb
min
room
temperatur
rt
postfix
osmium
tetroxid
fix
cell
dehydr
increas
concentr
ethanol
embed
epoxi
resin
mixtur
polymer
done
c
h
ultrathin
section
stain
uranyl
acet
section
view
digit
acquir
transmiss
electron
microscop
model
jem
jeol
ltd
japan
gener
lvlp
packag
cell
cotransfect
g
pcmv
g
cmvrha
g
cmvrna
use
calcium
phosphat
precipit
method
two
lvlp
express
differ
ident
flagtag
surfac
gener
one
lvlp
express
clade
ha
lvlp
express
subclad
ha
overnight
incub
cell
wash
pb
cultur
ml
complet
dmem
supplement
sodium
butyr
h
cell
cultur
ml
complet
dmem
lvlpcontain
supernat
harvest
h
load
onto
sucros
cushion
ultracentrifug
rpm
h
c
beckman
rotor
beckman
coulter
fullerton
ca
pellet
resuspend
pb
store
c
freezer
aliquot
use
immunogen
immun
sera
mice
anim
femal
balbc
mice
mu
musculu
age
week
purchas
shanghai
institut
biolog
scienc
anim
center
shanghai
china
hous
microisol
unit
allow
free
access
food
water
studi
mice
immun
pdna
pdna
lvlp
express
immun
mice
randomli
divid
four
group
mice
per
group
first
group
prime
boost
im
dna
plasmid
express
clade
second
group
prime
boost
im
dna
plasmid
express
clade
third
group
prime
im
dna
plasmid
express
clade
boost
im
lvlp
express
clade
last
group
prime
im
dna
plasmid
express
clade
boost
im
lvlp
express
clade
prime
boost
perform
interv
seven
day
immun
day
post
immun
blood
collect
via
retroorbit
sinu
clot
room
temperatur
h
c
overnight
tube
centrifug
sera
remov
heatinactiv
c
min
aliquot
pool
immun
sera
frozen
c
freezer
use
neutral
assay
procedur
accord
chines
depart
agricultur
guidelin
care
use
laboratori
anim
anim
welfar
act
chines
depart
agricultur
biosafeti
guidelin
microbiolog
biomed
laboratori
immun
challeng
ferret
ferret
male
adult
ferret
age
month
marshal
bioresourc
north
rose
ny
hous
pair
biosafeti
level
two
anim
facil
vaccin
battel
biomed
research
center
bbrc
columbu
oh
anim
screen
use
hi
assay
antibodi
three
circul
season
influenza
strain
anew
well
elisa
antibodi
intern
influenza
protein
ferret
elisa
antibodi
intern
influenza
protein
log
titer
hi
titer
viru
like
induc
natur
infect
bodi
weight
elisa
titer
use
group
ferret
ensur
distribut
prevaccin
elisa
titer
bodi
weight
compar
group
one
week
challeng
ferret
transfer
facil
bbrc
vaccin
eggderiv
formaldehydeinactiv
splitvirion
influenza
vaccin
produc
sanofi
pasteur
lyon
franc
use
reassort
clade
vaccin
seed
strain
obtain
nation
institut
biolog
standard
control
nibsc
potter
bar
uk
adjuv
squaleneinwat
emuls
vaccin
dose
ml
prepar
inject
mix
vaccin
adjuv
ferret
receiv
im
inject
day
adjuv
nonadjuv
influenza
vaccin
formul
tabl
control
ferret
receiv
salin
without
adjuv
blood
sampl
collect
anesthesia
day
two
month
second
vaccin
day
anim
anesthet
challeng
intranas
tcid
approxim
ld
wild
type
influenza
anim
monitor
daili
challeng
clinic
sign
influenza
temperatur
taken
twice
daili
use
subcutan
transpond
chip
bodi
weight
record
everi
day
day
challeng
end
studi
nasal
wash
perform
challeng
everi
day
challeng
half
anim
group
sacrif
day
challeng
surviv
anim
euthan
blood
sampl
collect
day
postchalleng
studi
approv
local
anim
ethic
committe
perform
condit
meet
us
standard
anim
experiment
ha
na
pseudotypebas
neutral
assay
madin
darbi
canin
kidney
mdck
cell
per
well
cultur
overnight
plate
complet
dmem
see
test
neutral
activ
mous
ferret
serum
sampl
serial
dilut
incub
indic
amount
pseudotyp
final
volum
l
c
h
mixtur
ad
cultur
mdck
cell
overnight
incub
cell
wash
phosphat
buffer
salin
pb
cultur
complet
dmem
medium
h
cell
detach
trypsinedta
treatment
luciferas
activ
rla
measur
describ
pn
assay
neutral
titer
serial
dilut
immun
sera
obtain
determin
percent
inhibit
transduct
effici
mdck
cell
transduc
pseudotyp
percent
inhibit
calcul
follow
rla
pseudotyp
medium
control
rla
pseudotyp
immun
serum
given
dilut
rla
pseudotyp
medium
control
inhibitori
concentr
inhibitori
concentr
report
dilut
given
immun
serum
result
reduct
luciferas
activ
respect
virus
dilut
ha
unit
incub
equal
volum
serial
dilut
immun
sera
sera
infect
ferret
min
room
temperatur
equal
volum
chicken
hors
red
blood
cell
ad
well
incub
continu
gentli
rock
plate
min
room
temperatur
button
format
score
evid
hemagglutin
inhibit
hi
mdck
cell
cell
per
well
seed
onto
cultur
plate
complet
dmem
overnight
test
neutral
activ
immun
sera
serial
dilut
sera
start
dilut
incub
wild
type
virus
final
volum
l
c
h
incub
mixtur
ad
onto
mdck
cell
mn
assay
wild
type
viru
use
tcid
describ
row
et
al
neutral
titer
serial
dilut
immun
sera
obtain
assess
cpe
mdck
cell
infect
viru
cpe
score
base
morpholog
mdck
cell
monolay
observ
microscop
see
supplementari
figur
detail
cpe
score
day
infect
cpe
compar
posit
control
virusinocul
cell
neg
control
mockinocul
cell
assay
perform
triplic
produc
express
pseudotyp
deriv
strain
cell
cotransfect
transfer
vector
phr
cmvluc
packag
vector
pcmvr
transfect
cultur
supernat
contain
pseudotyp
harvest
concentr
fraction
sucros
gradient
gag
protein
fraction
detect
specif
antibodi
fig
show
fraction
except
fraction
buoyant
densiti
protein
detect
along
gag
peak
gag
also
detect
faction
buoyant
densiti
thu
major
comigr
gag
protein
sucros
gradient
indic
incorpor
pseudotyp
particl
fig
electronmicrograph
show
pseudotyp
form
releas
surfac
packag
cell
fig
show
transduct
effici
measur
rel
luciferas
activ
rla
transduc
mdck
target
cell
expect
rla
cell
transduc
supernat
cell
transfect
phr
cmvluc
pcmvr
alon
similar
mock
transduct
contrast
low
measur
rla
detect
cell
transduc
supernat
cell
transfect
phr
cmvluc
pcmvr
plu
alon
contrast
cell
transduc
supernat
cell
transfect
phr
cmvluc
pcmvr
addit
exogen
na
higher
rla
detect
surprisingli
cell
transduc
supernat
cell
cotransfect
phr
cmvluc
pcmvr
plu
five
log
higher
rla
seen
express
alon
two
log
higher
express
combin
exogen
na
treatment
experi
repeat
three
time
similar
result
determin
pseudotyp
enter
cell
receptormedi
endocytosi
target
cell
pretreat
bafilomycin
nh
cl
agent
inhibit
acidif
endosom
block
endocytos
viru
enter
cytosol
bafilomycin
nh
cl
pretreat
cell
transduc
supernat
contain
pseudotyp
pseudotyp
express
envelop
latter
known
enter
cell
directli
pass
plasma
membran
fig
e
show
rla
cell
without
pretreat
nh
cl
bafilomycin
respect
either
pretreat
result
signific
reduct
transduct
effici
pseudotyp
particl
express
affect
transduct
effici
pseudotyp
express
envelop
signific
reduct
transduct
effici
pseudotyp
also
observ
mdck
target
cell
use
pretreat
data
shown
result
studi
suggest
pseudotyp
express
enter
cell
receptormedi
endocytosi
determin
sialidas
activ
na
requir
pseudotyp
releas
entri
cell
transfect
phr
cmvluc
pcmvr
plu
phr
cmvluc
pcmvr
plu
vsvg
phr
cmvluc
pcmvr
plu
envelop
transfect
cell
treat
without
variou
dose
neuraminidas
inhibitor
oseltamivir
phosphat
cultur
supernat
collect
use
transduc
target
cell
fig
show
treat
cell
oseltamivir
phosphat
induc
mark
dosedepend
decreas
transduct
effici
pseudotyp
express
pseudotyp
express
envelop
vsvg
contrast
treatment
target
cell
amount
oseltamivir
phosphat
reduc
transduct
effici
either
pseudotyp
envelop
pseudotyp
vsvg
pseudotyp
fig
thu
result
indic
enzymet
activ
na
requir
pseudotyp
releas
pseudotyp
entri
like
enzymet
activ
na
remov
sialicneuramin
receptor
surfac
packag
cell
viru
particl
help
pseudotyp
releas
taken
togeth
result
neuraminidas
inhibitor
oseltamivir
studi
result
bafilomycin
nh
cl
studi
strongli
suggest
mechan
cellular
entri
releas
pseudotyp
express
similar
wild
type
influenza
viru
next
gener
pseudotyp
panel
contain
pseudotyp
particl
express
eight
differ
common
pseudotyp
coexpress
cleavag
mutant
wsn
pseudotyp
express
vsvg
also
gener
use
control
eight
deriv
viru
strain
isol
human
infect
tabl
show
hana
pseudotyp
panel
gener
use
studi
hana
pseudotyp
panel
gener
measur
titer
pseudotyp
evalu
correl
dose
pseudotyp
particl
rla
titer
two
repres
hana
pseudotyp
tu
transduc
unit
ml
respect
pseudotyp
test
observ
near
perfect
correl
tu
rang
rla
rang
supplementari
figur
view
result
use
pseudotyp
dose
correspond
rla
unit
subsequ
pn
assay
develop
comparison
pn
assay
mn
assay
develop
pn
assay
use
pool
sera
mice
immun
one
two
immun
protocol
pdnapdna
primeboost
pdna
prime
vlp
boost
see
section
detail
specif
crossreact
immun
mous
sera
test
three
differ
ha
na
pseudotyp
control
pseudotyp
express
vsvg
three
ha
na
pseudotyp
contain
common
one
two
hemagglutinin
clade
subclad
pseudotyp
produc
use
cleavag
mutant
influenza
strain
wsn
shown
fig
immun
sera
elicit
prime
boost
plasmid
dna
express
subclad
effect
neutral
pseudotyp
express
subclad
sera
weakli
neutral
pseudotyp
express
clade
neutral
vsvg
pseudotyp
fig
sera
mice
immun
pdna
encod
subclad
follow
boost
lentiviruslik
particl
lvlp
express
subclad
show
similar
result
fig
likewis
sera
mice
prime
boost
pdna
encod
clade
effect
neutral
pseudotyp
express
clade
sera
weakli
neutral
subclad
neutral
pseudotyp
express
vsvg
fig
primeboost
studi
use
clade
pdna
follow
clade
lvlp
show
similar
result
fig
thu
result
studi
demonstr
pn
assay
exhibit
good
specif
reveal
quantit
differ
neutral
activ
immun
sera
gener
variou
clade
subclad
next
use
sera
vaccin
mice
compar
sensit
pn
assay
mn
assay
mn
assay
wild
type
use
pn
assay
hana
pseudotyp
express
wild
type
use
comparison
determin
effect
input
dose
pseudotyp
particl
measur
neutral
titer
pn
assay
titrat
immun
sera
three
dose
ha
na
pseudotyp
correspond
rla
valu
shown
tabl
good
correl
observ
neutral
titer
measur
mn
assay
pn
assay
tcid
use
mn
assay
rla
pn
assay
evalu
util
pn
assay
use
measur
neutral
antibodi
respons
vaccin
human
candid
vaccin
ferret
establish
clinic
relev
model
human
influenza
studi
compar
neutral
titer
sera
ferret
immun
monoval
splitvirion
inactiv
clade
vaccin
dose
g
ha
without
adjuv
figur
detail
inform
score
cpe
c
inhibit
tabl
show
neutral
titer
measur
pn
mn
hi
assay
appear
correl
well
moreov
pn
assay
also
appear
sensit
mn
hi
assay
detect
neutral
antibodi
respons
influenza
virus
exampl
two
immun
sera
elicit
splitvirion
equival
g
ha
alon
one
immun
sera
elicit
splitvirion
equival
g
ha
alon
exhibit
undetect
neutral
titer
measur
mn
hi
assay
contrast
measur
pn
assay
low
measur
neutral
titer
detect
thu
conclud
overal
good
correl
among
neutral
titer
measur
hi
mn
pn
assay
howev
immun
sera
low
neutral
activ
pn
assay
exhibit
greater
sensit
hi
mn
assay
evalu
sensit
antigen
specif
pn
assay
next
measur
neutral
titer
sera
immun
challeng
ferret
pseudotyp
express
one
seven
differ
pseudotyp
express
ha
describ
pseudotyp
also
express
common
na
strain
tabl
show
sera
clade
vaccin
ferret
crossneutr
least
one
heterolog
pseudotyp
exhibit
neutral
activ
pseudotyp
express
na
moreov
serum
sampl
ferret
immun
low
dose
vaccin
g
ha
show
low
undetect
neutral
titer
homolog
hana
pseudotyp
tabl
sera
anim
also
low
undetect
neutral
titer
heterolog
pseudotyp
express
clade
higher
neutral
titer
seen
clade
subclad
contrast
immun
sera
elicit
splitvirion
vaccin
dose
g
ha
adjuv
exhibit
much
higher
neutral
titer
homolog
pseudotyp
tabl
sera
also
show
higher
neutral
titer
heterolog
pseudotyp
express
clade
highest
neutral
titer
pseudotyp
express
clade
ha
lower
titer
observ
pseudotyp
express
ha
clade
lowest
neutral
activ
seen
pseudotyp
express
ha
clade
similarli
tabl
show
sera
ferret
immun
aloohadjuv
splitvirion
vaccin
dose
g
ha
exhibit
highest
neutral
titer
homolog
pseudotyp
sera
also
exhibit
highest
neutral
titer
heterolog
pseudotyp
express
differ
clade
subclad
neutral
titer
higher
clade
clade
challeng
sera
vaccin
ferret
exhibit
much
higher
neutral
titer
pseudotyp
also
show
detect
neutral
activ
pseudotyp
express
result
studi
conclud
ferret
immun
splitvirion
vaccin
prepar
clade
develop
neutral
antibodi
respons
strongli
crossreact
hana
pseudotyp
express
ha
differ
sublineag
clade
sera
immun
ferret
also
show
moder
crossneutr
pseudotyp
express
ha
clade
howev
sera
crossneutr
pseudotyp
express
intriguingli
upon
wild
type
challeng
immun
ferret
rapidli
produc
high
level
crossneutr
antibodi
clade
post
challeng
boost
seen
immun
ferret
regardless
dose
ha
adjuv
use
howev
higher
crossneutr
titer
seen
pseudotyp
express
ha
within
variou
clade
strain
within
clade
also
wild
type
challeng
sera
immun
ferret
show
neutral
antibodi
respons
crossreact
pseudotyp
express
also
detect
neutral
antibodi
respons
critic
prevent
clearanc
influenza
viru
infect
therefor
measur
neutral
antibodi
respons
may
use
influenza
serodiagnosi
correl
protect
immun
evalu
candid
season
pandem
influenza
vaccin
develop
effect
immunogen
capabl
elicit
neutral
antibodi
respons
genet
divers
strain
hpai
virus
requir
identif
ha
na
antigen
structur
contain
appropri
epitop
induc
protect
antibodi
moreov
develop
candid
pandem
influenza
vaccin
requir
standard
vitro
assay
allow
meaning
comparison
potenc
breadth
neutral
antibodi
respons
sera
bodi
fluid
vaccin
subject
nefken
et
al
gener
lentivir
pseudotyp
particl
express
ha
clade
influenza
strain
isol
patient
cambodia
use
pseudotyp
investig
test
neutral
activ
sera
infect
anim
human
demonstr
posit
correl
pseudotypebas
neutral
assay
mn
assay
yang
et
al
gener
lentivir
pseudotyp
coexpress
clade
mutant
form
well
na
strain
use
hana
pseudotyp
measur
amino
acid
residu
specif
recogn
monoclon
antibodi
gener
mice
vaccin
wild
type
triplemut
ha
howev
influenza
viru
evolv
differ
genet
clade
among
clade
shown
divers
subdivid
five
subclad
present
circul
hpai
virus
isol
human
fall
subclad
ha
clade
distinguish
antigen
thu
pseudotyp
express
singl
clade
may
fail
detect
neutral
activ
sera
infect
virus
clade
subclad
pseudotyp
express
alon
treat
exogen
ha
demonstr
suboptim
transduct
effici
limit
comparison
antibodi
titer
measur
pn
assay
versu
measur
convent
mn
hi
assay
studi
describ
method
produc
work
quantiti
ha
na
express
pseudotyp
prepar
panel
ha
na
pseudotyp
express
differ
hemagglutinin
major
clade
subclad
isol
human
infect
also
demonstr
ha
na
pseudotyp
mimic
wild
type
influenza
viru
mechan
cellular
entri
releas
use
immun
mous
ferret
sera
develop
pseudotypebas
neutral
pn
assay
show
assay
exhibit
good
specif
use
measur
quantit
differ
neutral
activ
differ
clade
subclad
influenza
virus
also
demonstr
excel
correl
neutral
titer
measur
mn
pn
assay
moreov
pn
assay
found
somewhat
sensit
mn
hi
assay
sinc
abl
detect
low
level
specif
antibodi
respons
level
detect
assay
final
use
sera
ferret
immun
adjuv
unadjuv
split
virion
vaccin
show
util
pn
assay
sensit
quantifi
assay
measur
neutral
antibodi
respons
divers
clade
subclad
experi
compar
antibodi
respons
measur
use
pn
assay
measur
mn
hi
assay
addit
advantag
sensit
specif
demonstr
studi
pn
assay
sever
advantag
mn
hi
assay
measur
antibodi
respons
hpai
virus
tabl
firstli
pseudotyp
particl
undergo
singleround
replic
indic
cell
line
produc
infecti
progeni
virus
therefor
pn
assay
requir
contain
facil
secondli
unlik
hi
assay
pn
assay
directli
measur
effect
neutral
antibodi
block
viru
entri
cell
thirdli
pn
assay
rapid
sinc
mn
assay
take
day
complet
pn
assay
conduct
day
addit
result
illustr
import
choos
appropri
pseudotyp
dose
measur
neutral
antibodi
respons
hpai
virus
pn
assay
use
evalu
neutral
antibodi
titer
elicit
vaccin
candid
higher
input
dose
ha
na
pseudotyp
compar
tcid
use
standard
mn
assay
use
pn
assay
neutral
titer
immun
sera
bodi
fluid
overestim
contrast
use
serodiagnosi
lower
input
dose
hana
pseudotyp
may
use
serv
increas
sensit
assay
without
sacrif
specif
result
show
requir
low
ph
entri
ha
na
pseudotyp
pseudotyp
express
alon
describ
nefken
et
al
result
also
point
major
limit
use
pseudotyp
express
ha
singl
clade
serodiagnosi
studi
show
pseudotyp
coexpress
ha
na
much
higher
transduct
effici
pseudotyp
express
alon
plu
exogen
na
suggest
cotransfect
lentivir
transfer
vector
alon
exogen
na
treatment
pseudotyp
releas
result
lower
level
pseudotyp
product
compar
pseudotyp
coexpress
ha
na
moreov
show
signific
quantit
differ
antigenec
immunogenec
among
differ
hemagglutinin
variou
clade
subclad
thu
pseudotyp
express
singl
clade
may
fail
detect
neutral
activ
sera
human
anim
infect
virus
clade
subclad
avian
influenza
viru
evolv
differ
clade
base
chang
genet
sequenc
analysi
among
clade
subdivid
five
subclad
hana
pseudotyp
panel
studi
consist
clade
would
desir
expand
panel
cover
hemagglutinin
known
clade
subclad
immunogenec
crossreact
hemagglutinin
among
divers
strain
studi
greater
detail
determin
extent
genet
differ
correspond
differ
serotyp
addit
pseudotyp
express
subtyp
ha
na
also
studi
particularli
view
three
recent
report
show
variou
monoclon
antibodi
gener
hpai
infect
individu
antiha
monoclon
antibodi
gener
season
influenza
vaccin
crossreact
ha
influenza
subtyp
final
mani
potenti
applic
pn
assay
measur
neutral
antibodi
respons
immun
infect
sera
bodi
fluid
exampl
assay
could
adapt
use
screen
drug
candid
block
entri
releas
virus
screen
monoclon
antibodi
final
could
adapt
use
tool
map
neutral
epitop
construct
pseudotyp
express
chimera
sitedirect
random
mutant
